« Return to News | Technology Solutions

Accelrys expands into QA/QC with VelQuest acquisition

Monday, January 9, 2012 09:23 AM

Accelrys, a scientific enterprise R&D software and services company, paid $35 million in cash to acquire privately held VelQuest, a lab execution and instrument data capture software company.

The acquisition extends Accelrys’ reach beyond research and into quality assurance and quality control phases of product development. Using VelQuest’s procedure execution management products (SmartLab, SmartBatch, and gmpLIMS), Accelrys said it will speed time to innovation with up to 10 times reduction in compliance risk.

Some integration has already taken place between the VelQuest offerings and existing Accelrys solutions, opening the door to further synergies and downstream opportunities as a result of this acquisition.

“Joining forces with Accelrys is a real win for the many life sciences organizations we serve,” said Ken Rapp, president and CEO of VelQuest. “In addition, with Accelrys’ broad market reach, the utilization of VelQuest’s products beyond life sciences offers significant opportunities. Most importantly, the inherent synergies between Accelrys and VelQuest products and their critical roles in the development to commercialization phases of the pharmaceutical R&D process offer customers a comprehensive, single-source informatics offering along the entire lab-to-plant value chain.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.